A Two-part, Phase I, Open-label, Multicenter, Two-period, One-sequence Study to Investigate the Effect of Itraconazole and Rifampin on the PK of Vemurafenib at Steady State
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Itraconazole (Primary) ; Rifampicin (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Pharmacokinetics
- Sponsors Genentech
- 16 Mar 2017 Planned End Date changed from 1 Jan 2018 to 29 Nov 2018.
- 16 Mar 2017 Planned primary completion date changed from 1 Jan 2018 to 29 Nov 2018.
- 01 Jun 2016 Status changed from not yet recruiting to recruiting.